Networking in rare cancers: What was done, what's next.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
01 2019
Historique:
received: 26 03 2018
accepted: 28 03 2018
pubmed: 25 4 2018
medline: 4 1 2019
entrez: 25 4 2018
Statut: ppublish

Résumé

Rare cancers represent approximately one fourth of all cancers. Despite being a heterogeneous group of diseases, they share similar problems including lack of expertise, issues in quality of care, discrepancies in outcome and limitations in research. Traditionally, centralization of rare cancer patients to dedicated reference centres has been recommended to ensure expertise, multidisciplinarity and access to innovation. However, centralization entails health migration, rationing of resources and a potential failure in routine care. By ensuring appropriate care to all patients regardless the point of access, networking seems the most appropriate answer to the problem of rare cancers. The launch of the Joint Action on Rare Cancers as well as the recent establishment of the European Reference Networks represent for the first time a concrete opportunity to make networking a reality and ultimately reduce disparities and improve outcome in these diseases.

Identifiants

pubmed: 29685758
pii: S0748-7983(18)31000-X
doi: 10.1016/j.ejso.2018.03.030
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

16-18

Informations de copyright

Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Auteurs

Anna Maria Frezza (AM)

Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Via G. Venezian 1, 20133, Milan, Italy. Electronic address: annamaria.frezza@istitutotumori.mi.it.

Annalisa Trama (A)

Evaluative Epidemiology Unit, IRCCS Fondazione Istituto Nazionale Tumori, Via G. Venezian 1, 20133, Milan, Italy.

Jean-Yves Blay (JY)

Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, 28 Rue Laennec, 69373, Lyon, France.

Paolo G Casali (PG)

Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Via G. Venezian 1, 20133, Milan, Italy; Department of Medical Oncology and Haemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH